Evidence map›Paper›PMID 42236697›Full record

ArticleCell death & disease2026

Cdk1-phosphorylated Nur77 accumulates at the centrosome during mitosis to regulate the Cep192-PLK1 signaling axis.

Guobin Xie, Qiqiang Wang, Mingxuan Du, Yuqi Zhou, Ziwen Chen, Shuangzhou Peng, Hualan Zhou, Xiaoli Zhang, Qi Cai, Gulimiran Alitongbieke and 13 more

Abstract read
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Guobin Xie *School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China. xieguobin@xmu.edu.cn.ORCID http://orcid.org/0009-0008-2481-9682
Qiqiang Wang *School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Mingxuan Du *School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Yuqi Zhou *School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Ziwen ChenSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Shuangzhou PengSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Hualan ZhouSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Xiaoli ZhangSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Qi CaiSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Gulimiran AlitongbiekeSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Xiaohui ChenDepartment of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.ORCID http://orcid.org/0000-0002-0397-1860
Jiajin YiSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Xiaoxuan YeSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Hongli WangSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Xiaohong YeSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Lin XuSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Boning NiuSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Haishan WangNucMito Pharmaceuticals Co. Ltd., Xiamen, China.ORCID http://orcid.org/0000-0002-7959-7377
Yihong KeSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Yang XuSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Hu ZhouSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Ying SuNucMito Pharmaceuticals Co. Ltd., Xiamen, China.
Xiao-Kun ZhangSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China. xkzhang@xmu.edu.cn.ORCID http://orcid.org/0000-0001-9941-6222

Funding

China Postdoctoral Science Foundation 2021M691886China Postdoctoral Science Foundation 2023M732956Fujian Provincial Department of Science and Technology (Department of Science and Technology of Fujian Province) 2023Y0003National Natural Science Foundation of China (National Science Foundation of China) 82203313
6 · The paper itself

Abstract

The orphan nuclear receptor Nur77 is a multifunctional regulator involved in diverse cellular processes, including proliferation, survival, and apoptosis, through both transcription-dependent and -independent mechanisms. This regulatory complexity underscores the need for mechanistic studies in defined biological contexts. Here, we uncover a previously unrecognized non-genomic function of Nur77 at the centrosome that promotes mitotic progression in cancer cells. We show that Nur77 is phosphorylated at threonine 143 by cyclin-dependent kinase 1 (Cdk1), leading to its accumulation at the centrosome, where it binds the scaffold protein Cep192. This interaction is critical for maintaining centrosome integrity in tumor cells and facilitating the recruitment of Polo-like kinase 1 (PLK1), a key driver of centrosome maturation. Notably, Cdk1-mediated phosphorylation of Nur77 is aberrantly elevated in tumors, contributing to malignant proliferation through its mitotic role. Depletion of Nur77 or treatment with NMA39, a novel small-molecule Nur77 modulator that disrupts the Nur77-Cep192 interaction, results in mitotic arrest and cell death in tumor cells. These findings reveal a tumor-selective mitotic function of Nur77 and establish a mechanistic rationale for targeting phospho-Nur77 signaling as a cancer vulnerability.

Indexed as

CDC2 Protein KinaseCell Cycle ProteinsCentrosomeMitosisNuclear Receptor Subfamily 4, Group A, Member 1Protein Serine-Threonine KinasesProto-Oncogene ProteinsAnimalsCell Line, TumorHumansPhosphorylationPolo-Like Kinase 1Signal TransductionCDC2 Protein KinaseCDK1 protein, humanCell Cycle ProteinsNR4A1 protein, humanNuclear Receptor Subfamily 4, Group A, Member 1Polo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene Proteins

Identifiers

PMID42236697
PMCPMC13448657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.